Tobias Suter

Tobias Suter

Auto-generated profile, based on publicly available information

Tobias Suter

Clinical Immunology, University Hospital of Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2011 in Nature Immunology
Verified
Journal Article
Closed access
LCLaura Codarri
Laura Codarri
GGGabor Gyülvészi
Gabor Gyülvészi
VTVinko Tosevski
Vinko Tosevski
LHLysann Hesske
Lysann Hesske
AFAdriano Fontana
Adriano Fontana
BBBurkhard Becher
Burkhard Becher

1 December 2015 in Cell
Verified
Journal Article
Closed access
SHSamia Habbas
Samia Habbas
MSMirko Santello
Mirko Santello
DBDenise Becker
Denise Becker
HSHiltrud Stubbe
Hiltrud Stubbe
GZGiovanna Zappia
Giovanna Zappia
AVAndrea Volterra
Andrea Volterra

24 January 2006 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
CFClaudia Ferrara
Claudia Ferrara
PBPeter Brünker
Peter Brünker
TSTobias Suter
Tobias Suter
SMSamuel Moser
Samuel Moser
UPUrsula Püntener
Ursula Püntener
PUPablo Umaña
Pablo Umaña

19 May 2014 in Journal of Experimental Medicine
Verified
Journal Article
Open access
JDJuan Dubrot
Juan Dubrot
FDFernanda V. Duraes
Fernanda V. Duraes
LPLambert Potin
Lambert Potin
FCFrancesca Capotosti
Francesca Capotosti
DBDale Brighouse
Dale Brighouse
SHStéphanie Hugues
Stéphanie Hugues
Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been described to tolerize self-reactive CD8+ T cells in LNs. Although LNSCs express MHCII, it is unknown whether they can also impact CD4+ T cell functions. We show that the promoter IV (pIV) of class II transactivator (CIITA), the master regulator of MHCII expression, controls endogenous MHCII expression by LNSCs. Unexpectedly, LNSCs also acquire peptide–MHCII complexes from DCs and induce CD4+ T cell dysfunction by presenting transferred complexes to naive CD4+ T cells and preventing their proliferation and survival. Our data reveals a novel, alternative mechanism where LN-resident stromal cells tolerize CD4+ T cells through the presentation of self-antigens via transferred peptide–MHCII complexes of DC origin.

18 May 2004 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
Salomé Leibundgut-LandmannSalomé Leibundgut-Landmann
Salomé Leibundgut-Landmann
JWJean‐Marc Waldburger
Jean‐Marc Waldburger
MKMichał Szymon Krawczyk
Michał Szymon Krawczyk
LOLuc A. Otten
Luc A. Otten
TSTobias Suter
Tobias Suter
WRWalter Reith
Walter Reith
The class II transactivator (CIITA) has been referred to as the "master control factor" for the expression of MHC class II (MHCII) genes. As our knowledge on the specificity and function of CIITA grows, it is becoming increasingly evident that this sobriquet is entirely justified. First, despite extensive investigations, the major target genes of CIITA remain those implicated in the presentation of antigenic peptides by MHCII molecules. Although other putative target genes have been reported, the contribution of CIITA to their expression remains indirect, controversial or comparatively minor relative to its decisive role as a regulator of MHCII and related genes. Second, the most important parameter dictating MHCII expression is by far the expression pattern of the gene encoding CIITA (MHC2TA). The vast majority of signals that activate or repress MHCII expression under physiological and pathological situations converge on one or more of the three alternative promoters that drive transcription of the MHC2TA gene. In short, with respect to its specificity and its exquisitely controlled pattern of expression, CIITA is by a long stretch the single most important transcription factor for the regulation of genes required for MHCII‐restricted antigen‐presentation.

1 May 2016 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
MFM.T. Ferretti
M.T. Ferretti
MMM. Merlini
M. Merlini
CSC. Späni
C. Späni
CGC. Gericke
C. Gericke
NSN. Schweizer
N. Schweizer
RNR.M. Nitsch
R.M. Nitsch
Cerebral beta-amyloidosis, one of the pathological hallmarks of Alzheimer's disease (AD), elicits a well-characterised, microglia-mediated local innate immune response. In contrast, it is not clear whether cells of the adaptive immune system, in particular T-cells, react to cerebral amyloidosis in AD. Even though parenchymal T-cells have been described in post-mortem brains of AD patients, it is not known whether infiltrating T-cells are specifically recruited to the extracellular deposits of beta-amyloid, and whether they are locally activated into proliferating, effector cells upon interaction with antigen-presenting cells (APCs). To address these issues we have analysed by confocal microscopy and flow-cytometry the localisation and activation status of both T-cells and APCs in transgenic (tg) mice models of AD-like cerebral amyloidosis. Increased numbers of infiltrating T-cells were found in amyloid-burdened brain regions of tg mice, with concomitant up-regulation of endothelial adhesion molecules ICAM-1 and VCAM-1, compared to non-tg littermates. The infiltrating T-cells in tg brains did not co-localise with amyloid plaques, produced less interferon-gamma than those in controls and did not proliferate locally. Bona-fide dendritic cells were virtually absent from the brain parenchyma of both non-tg and tg mice, and APCs from tg brains showed an immature phenotype, with accumulation of MHC-II in intracellular compartments. These results indicate that cerebral amyloidosis promotes T-cell infiltration but interferes with local antigen presentation and T-cell activation. The inability of the brain immune surveillance to orchestrate a protective immune response to amyloid-beta peptide might contribute to the accumulation of amyloid in the progression of the disease.